Clinical trials: Healthy Participants
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families
This trial studies how well Young Melanoma Family Facebook intervention or Healthy Lifestyle Facebook intervention works in improving skin examination in participants with melanoma and their families.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
- Trial name
- NCT03677739
- Testing
- Informational Intervention, Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Healthy
First In Human Study Of Increasing Oral Doses Of PF-04634817
The study will evaluate the hypothesis that at doses and plasma concentrations which affect pharmacodynamic markers of activity at the chemokine receptors, CCR2 and CCR5, the compound is safe and well tolerated.
- Trial name
- NCT01098877
- Testing
- PF-04634817
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy, Pain
A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)
The goal of this study is to learn what happens to MK-4318 in a person's body over time. Researchers will compare what happens to levels of MK-4318 in people's blood when it is taken with and without diltiazem.
- Trial name
- NCT06692647
- Testing
- MK-4318, Diltiazem
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Safety and Tolerability of CFTX-1554 in Healthy Subjects
The study will consist of 2 parts, i.e. a single ascending dose part with integrated food effect assessment and assessment of relative bioavailability (Part A), and a multiple ascending dose part (Part B).
- Trial name
- NCT05260658
- Testing
- CFTX-1554
- Where
- Netherlands
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Confo Therapeutics
Healthy
Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects
To assess safety, pharmacokinetics and the effect of BIBR 1048 MS on coagulation parameters in healthy volunteer subjects.
- Trial name
- NCT02170740
- Testing
- BIBR 1048 MS - low dose, BIBR 1048 MS - high dose, BIBR 1048 MS + Pantoprazole
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
H1N1 Influenza Healthy Volunteers
Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model
Background: Researchers want to see if a new drug reduces flu disease in people treated with this drug versus a placebo. The drug has an antibody that may help the immune system fight the flu. Placebo is only sugar and water.
- Trial name
- CR6261 (NCT02371668)
- Testing
- CR6261
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Food-Effect Study of BPI-16350 in Healthy Subjects
This study is intended to quantify the effect of food on the pharmacokinetics of BPI-16350. Subjects will be randomized to a crossover sequence at a 1:1 ratio and administered the dose of BPI-16350 on Day 1 in Period 1 and on Day…
- Trial name
- NCT05316259
- Testing
- BPI-16350
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Healthy Subjects
Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth
A clinical study to evaluate the effect of a commercial mouth rinse on plaque re-growth
- Trial name
- NCT01122862
- Testing
- 0.12% chlorhexidine mouthrinse, Cosmetic mouthrinse, Sterile water
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Peripheral Arterial Disease
Platelets Induced Vasodilation, in Vitro and in Vivo Study
The aim of the study is to show the implication of platelets in vasodilation using in vivo and in vitro analysis and to compare the effects of placebo, aspirin and Clopidogrel in this interaction platelets/vessels.
- Trial name
- NCT00152646
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Compartment Syndromes
SWISS_CLEARANCE - Compartment Compressibility Monitoring Using CPM#1
Compartment syndrome is a very serious musculoskeletal disorder, which can lead to potentially devastating consequences, such as limb amputation and life- threatening conditions.
- Trial name
- NCT05483946
- Testing
- Measurement of compartment compressibility
- Where
- Switzerland
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Compremium AG
Healthy Volunteers
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
This study will be a fixed sequence drug-drug interaction study in healthy postmenopausal females, conducted at multiple study sites
- Trial name
- NCT05438303
- Testing
- AZD9833, Midazolam, Omeprazole
- Where
- 2 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers
The purpose of this study is to investigate safety and toleration of multiple oral doses as well as the time course of PF-03893787 concentration in the blood following dosing by oral solution.
- Trial name
- NCT00992342
- Testing
- PF-03893787
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin
This is a Phase 4, single center, open label, fixed-sequence, multiple dose, 2-way drug-drug interaction study.
- Trial name
- NCT01422369
- Testing
- Pitavastatin (NK-104), Darunavir/Ritonavir (Prezista)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Mantle Cell Lymphoma, COVID-19
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
This Phase 1 study is being conducted to support the clinical development of acalabrutinib in hospitalized patients who are unable to swallow acalabrutinib tablet or capsule due to respiratory failure, eg, they may require…
- Trial name
- NCT04564040
- Testing
- Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects
This is a FIH, randomized, double- blind, placebo-controlled, dose -escalation study to investigate the safety, tolerability, PK, and PD of ENN0403 after single and multiple oral dose administration in healthy adult subjects.
- Trial name
- NCT05506540
- Testing
- ENN0403 1mg, ENN0403 4mg, ENN0403 10mg
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- EnnovaBio
Hypercholesterolemia and Hyperlipidemia
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
In order to meet the preferences and needs of different patients for injection sites and improve the medication compliance of patients, it is planned to compare the bioavailability, pharmacokinetics, pharmacodynamic and safety…
- Trial name
- NCT05370950
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants
The purpose of this study is to evaluate the safety, acceptability, pharmacokinetics (what the body does to the medication), and ex vivo (tested outside the body) pharmacodynamics (what the medication does to the body) of TMC278…
- Trial name
- NCT01656018
- Testing
- TMC278, Long acting (LA)
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Gout, Hyperuricemia
Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
This is a randomized, double-blind, 3-period crossover phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on febuxostat pharmacokinetics (PK) and pharmacodynamics (PD) and to evaluate the…
- Trial name
- NCT00995618
- Testing
- Tranilast, Febuxostat, Combination - Tranilast and Febuxostat
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Nuon Therapeutics, Inc.
Hepatic Insufficiency, Healthy
Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
The main objective of this study is to assess the effect of mild, moderate and severe hepatic impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral administration of BI 10773 as a single dose.
- Trial name
- NCT01111318
- Testing
- BI 10773
- Where
- Romania
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants
The purpose of this study is to evaluate the effect of food on the pharmacokinetics of a single oral dose of fezolinetant under fasted and fed conditions in healthy female participants.
- Trial name
- NCT04641260
- Testing
- Fezolinetant
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.